ISSN 1004-6879
CN 13-1154/R
Journal of Chengde Medical University ›› 2019, Vol. 36 ›› Issue (3): 214-216.
Previous Articles Next Articles
LIANG Yu-shu, YE Wei-xuan, PENG Jing-qin, et al
Received:
Online:
Published:
梁玉书, 叶伟煊, 彭景钦, 范发才
基金资助:
Abstract: Objective: To observe the effects of Montelukast combined Budesonide formotello on exhaled nitric oxide (FeNO) and pulmonary function of cough variant asthma (CVA) patients. Methods: 60 CVA patients were randomly divided into observation group and control group with 30 patients in each group. The patients in control group were treated with Budesonide formoterol inhalation; While the patients in observation group were treated with Budesonide formoterol inhalation combined Montelukast. The FeNO and pulmonary function of patients in both groups were compared after treating for 4 weeks. Results: After treatment, the FeNO of patients in 2 groups were all significantly decreased (P<0.05); And the FeNO of patients in observation group after treatment was significantly lower than control group (P<0.05). After treatment, the forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC of both groups increased significantly (P<0.05); And, the FEV1, FVC and FEV1/FVC of patients in observation group after treatment was significantly lower than control group (P<0.05). Conclusions: Compared with Budesonide formotello alone, treating CVA with Montelukast Combined Budesonide formotello can inhibit respiratory inflammation and improve pulmonary function better, so it is worthy of clinical application.
Key words: Montelukast, Budesonide formotello, Cough variant asthma (CVA), Exhaled nitric oxide (FeNO), Pulmonary function
摘要: 目的:观察孟鲁司特联合布地奈德福莫特罗对咳嗽变异性哮喘(CVA)患者呼出气一氧化氮(FeNO)及肺功能的影响。方法:60例CVA患者随机分为对照组与观察组各30例,对照组给予吸入布地奈德福莫特罗吸入剂治疗,观察组在对照组治疗方案的基础上加用孟鲁司特口服。治疗4周后对比两组患者的FeNO和肺功能。结果:治疗后,两组患者的FeNO均较治疗前明显降低(P<0.05);并且,观察组治疗后的FeNO明显低于对照组(P<0.05)。治疗后,两组患者的第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC均较治疗前明显提高(P<0.05);并且,观察组治疗后的FEV1、FVC、FEV1/FVC均明显高于对照组(P<0.05)。结论:与单纯应用布地奈德福莫特罗比较,孟鲁司特联合布地奈德福莫特罗治疗CVA能更好地抑制呼吸道炎症反应,改善肺功能,值得临床上推广应用。
关键词: 孟鲁司特, 布地奈德福莫特罗, 咳嗽变异性哮喘, FeNO, 肺功能
CLC Number:
R562.2
LIANG Yu-shu, YE Wei-xuan, PENG Jing-qin, et al. EFFECTS OF MONTELUKAST COMBINED BUDESONIDE FORMOTELLO ON FENO ANDPULMONARY FUNCTION OF CVA PATIENTS[J]. Journal of Chengde Medical University, 2019, 36(3): 214-216.
梁玉书, 叶伟煊, 彭景钦, 范发才. 孟鲁司特联合布地奈德福莫特罗对CVA患者FeNO及肺功能的影响*[J]. 承德医学院学报, 2019, 36(3): 214-216.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://tougao.cdmc.edu.cn:8088/EN/
http://tougao.cdmc.edu.cn:8088/EN/Y2019/V36/I3/214